PLIVA d.d. ("PLIVA") will today host its fourth R&D Day in London, where it will update investors and analysts on the most recent developments in its R&D pipeline.
Radan Spaventi, Vice-President of PLIVA's Management Board and CSO, commented: "I am pleased to say that PLIVA is continuing to deliver upon the promises made to investors. The progress shown in our R&D pipeline clearly shows that PLIVA is successfully developing a wide range of generic, specialty & NCE products. We believe that this strong pipeline will ensure sustainable growth as well as the transition to a non-azithromycin dependent business by 2006."
Zelimir Vuksic, Vice-President of PLIVA's Management Board and President of Pharmaceuticals, added: "With our third quarter results, our pharmaceuticals business clearly showed that PLIVA began to deliver the organic growth that investors have been expecting from us. With over 700 registrations pending market approval, and more than 60 molecules continuously in development, we believe that we will only continue to prove our strategy a success in the future."